{"id":"NCT01691768","sponsor":"Centre for the AIDS Programme of Research in South Africa","briefTitle":"Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services","officialTitle":"Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-10","primaryCompletion":"2015-04","completion":"2015-12","firstPosted":"2012-09-25","resultsPosted":"2019-11-26","lastUpdate":"2019-11-26"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"1% tenofovir gel","otherNames":[]}],"arms":[{"label":"Intervention","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the effectiveness of an implementation model which integrates tenofovir gel provision into existing family planning services.","primaryOutcome":{"measure":"Mean Number of Returned Used Applicators Per Month (i.e in 30 Days)","timeFrame":"Between 2012 to 2015, up to 28 months","effectByArm":[{"arm":"Intervention","deltaMin":5.2,"sd":null},{"arm":"Control","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":2},"locations":{"siteCount":2,"countries":["South Africa"]},"refs":{"pmids":["20643915","28348164","25527071"],"seeAlso":["http://www.caprisa.org"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":189},"commonTop":["Vaginal discharge","Headache","Nasopharyngitis","Blood pressure diastolic increased","Diarrhoea"]}}